The Association for Clinical Oncology (ASCO) sent a letter to congressional leadership urging more action to address current drug shortages exacerbated by COVID-19 and to prevent future drug shortages.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Association for Clinical Oncology (ASCO) joined more than 100 other health organizations in sending a letter to congressional leadership urging them to include the targeted and limited liability protections in the bipartisan “Coronavirus Provider Protection Act” (H.R. 7059) in the next COVID-19 relief package.
The Association for Clinical Oncology (ASCO) submitted comments to the Department of Defense (DoD) in response to the TRICARE Coverage and Payment for Certain Services in Response to the COVID–19 Pandemic interim final rule. The rule allows TRICARE to reimburse providers for audio-only services during the COVID-19 Public Health Emergency (PHE).
Providers have until June 3, 2020, to apply for the Provider Relief Fund, which has been allocated by the U.S. Department of Health and Human Services (HHS) for general distribution to Medicare facilities and providers impacted by COVID-19.
The Association for Clinical Oncology (ASCO) recently sent a letter to House and Senate leadership urging their support for policies to increase diversity in clinical trials, including the CLINICAL TREATMENT Act (H.R. 913), in a future COVID-19 response package.
The latest legislative package aimed at stabilizing the United States (U.S.) economy and bolstering the health care system during the COVID-19 crisis was recently signed into law. The ‘‘Paycheck Protection Program and Health Care Enhancement Act,’’ provides about $475 billion to key programs under the CARES Act, including the Paycheck Protection Program (PPP), and provides additional funds for COVID-19 testing and to aid hospitals and small businesses.
To help ensure that health care providers have the resources necessary to care for patients during the COVID-19 pandemic, Congress and the Centers for Medicare & Medicaid Services (CMS) took action to provide direct financial support to providers who have been impacted by the emergency. The Coronavirus Aid, Relief, and Economic Security (CARES) Act and new guidance from CMS both contain provisions to provide financial support to qualified providers.
In testimony submitted to Congress about the federal budget for FY 2021, ASCO thanked lawmakers for increasing funding for cancer research in FY2020 and urged them to increase funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the Centers for Disease Control and Protection (CDC) in the year ahead.
Congress recently passed a third legislative package focused on stabilizing the United States economy and shoring up the health care system to ensure it is prepared to deal with the COVID-19 crisis. The bill includes key provisions that will impact the cancer care community, as well as patients with and survivors of cancer.
The Association for Clinical Oncology (ASCO) is urging the White House and leaders in Congress to swiftly work together to meet the needs of patients and health care professionals in response to the COVID-19 crisis.
On March 18, the President signed into law the second emergency supplemental package designed to respond to COVID-19, which requires private health plans, Medicare Advantage Plans, TRICARE, veterans’ plans, federal workers' health plans, and the Indian Health Service to cover the COVID-19 diagnostic test at no cost to the patient and without prior authorization, as long as the patient visits a health care provider, urgent care center, or emergency room before receiving the test.
The Association for Clinical Oncology (ASCO) recently held a briefing on Capitol Hill to inform policymakers and other stakeholders about the need for the bipartisan CLINICAL TREATMENT Act (H.R. 913), which would guarantee coverage of the routine care costs for Medicaid enrollees with life-threatening conditions participating in clinical trials.
On March 6, 2020, President Trump signed into law the Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020. This $8.3 billion package provides funding for the country’s response to coronavirus, including amongst its many provisions an emergency telehealth waiver, vaccine development, support for state and local governments, and assistance for affected small businesses.
Highlights from the bill include:
Emergency Telehealth Waiver ($500 million estimated cost)
The Association for Clinical Oncology (ASCO) recently joined more than a dozen other health groups in sending a letter to leaders of the Senate Committee on Health, Education, Labor, and Pensions (HELP) to convey their support of S.2723—The Mitigating Emergency Drug Shortages (MEDS) Act—which would help reduce drug shortages by addressing vulnerabilities in the drug supply chain. The letter urges the committee to quickly advance this important piece of legislation.
The Association for Clinical Oncology (ASCO) is calling on Members of Congress to continue their support for federally funded research by providing $44.7 billion for the National Institutes of Health (NIH), including $6.9 billion for the National Cancer Institute (NCI) in Fiscal Year (FY) 2021. The $3 billion funding increase for NIH will help the agency continue to regain some of the ground it lost after years of effectively flat budgets so the U.S. biomedical research enterprise can continue its important work in support of new advances and cures for patients.